In an ultra-competitive skincare landscape split between e-commerce, mass retail, specialty stores, and selective perfumeries, one channel quietly controls more than half of the total market. As of the most recent available data, the pharmacy and parapharmacy channel accounted for over 50% of France's total cosmetics market in value in 2023, according to GERS market data.
For a channel often treated as a secondary option behind selective retail, that scale is easy to underestimate from outside France.
What is driving the growth
That dominant position is not static. In 2023, cosmetics sales inside French pharmacies and parapharmacies grew by roughly 14% compared to the previous year, reaching 2.1 billion euros in sell-out value. The GERS figures break that growth into three effects: innovation accounted for roughly 150 million euros of the increase, pricing added around 60 million euros, and volume contributed about 45 million euros.
Innovation leading the way matters. It points to pharmacies stocking products consumers specifically want, rather than simply seeing more foot traffic. Three segments grew fastest that year: facial skincare, up 19%, sun care, up 16%, and body care, up 12%.
Why the trust factor matters here
In France, a pharmacist's recommendation carries the weight of the healthcare system behind it. In a landscape saturated with informal advice from social media and online forums, that weight is difficult for a mass-retail shelf placement or a selective retail display to replicate on its own.
That dynamic favors brands that can support their claims with real formulation depth: documented actives, dermatological testing, ingredient transparency. Proof matters more than presentation in this channel.
Established leaders, and real openings
The top dermocosmetics brands by revenue in French pharmacies read like a familiar list: Avène, La Roche-Posay, Nuxe, Bioderma, and Caudalie. These are established names with long-standing pharmacist relationships built over years, not campaigns, and their growth in 2023 stayed comparatively stable, carried by the strength of formulas already known at the counter.
But the channel is not closed to new entrants, and three brands in 2023 show what breaking through actually looks like. La Rosée, created in 2015, became the sixth best-selling dermocosmetics brand in French pharmacies, present in more than 9,000 pharmacies, generating over 70 million euros in revenue in 2023, up 35 million euros from the year before. SVR, a heritage brand dating back to the 1960s, added 22 million euros in revenue in 2023, a 51% jump, on the strength of a concentrated, expert-positioned range aimed at consumers over 30. CeraVe, an L'Oréal-owned brand launched in 2005, grew 112% in 2023, adding 20 million euros in a single year, driven by an accessible price point and strong traction with buyers under 25 through social media.
Three different strategies produced three different growth curves, all inside the same historically stable channel.
What this means for a foreign brand
Entering the French pharmacy channel is not a distribution decision made in isolation. It requires a scientific dossier that can stand up to pharmacist scrutiny, regulatory compliance specific to how claims are framed in this channel, and, in most cases, a distribution network built for pharmacy logistics rather than general retail.
That is a higher bar than entering through e-commerce or selective retail. Based on both the channel's overall weight and the challengers currently gaining share inside it, that higher bar is currently paying off, whether the entry strategy leans on clinical credibility, as SVR did, or on price and social proof, as CeraVe did.
The takeaway
In France, pharmacy holds the dominant position in cosmetics distribution, not a niche or fallback role, as of the latest available data, and it still has room for new entrants who can either out-formulate or out-market the brands already on the shelf.
For a brand weighing where to place its first bet in France, that combination of scale and openness is worth factoring in before the channel decision is made, not after.